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SUMMARY
InMarch 1998theDepartmentofHealthandSocialServicesissuedprescribingguidelinesforthe
use ofdrugs for dementia. A criterion based audit of202 consecutive cases was undertaken over
one year which showed that the prescribing guidelines in general were being followed. A small
numberofpatients,3,wereprescribedthedrugsoutsidetheguidelinesandmostfailures, 10,were
due to poor recording ofdata in the clinical record. Despite the recommendation ofthe DHSS no
agreed shared care protocols have been implemented but this does not seem to have affected
access to these drugs.
As a result of this audit changes have been made with regard to documentation of patient
assessmentsandsuggestionsmadetoreviewClinicalResourceEfficiencySupportTeam(CREST)
guidelines.
INTRODUCTION
Dementia is an organic syndrome characterised
by a progressive decline in intellect, behaviour
and personality in which there is no clouding of
consciousness. Itisestimatedthat3.2% ofpeople
aged70-79and 10.8% ofthoseaged80- 89years
have dementia of the Alzheimer's type (DAT).1
The condition is usually irreversible and until
recently there have been no drugs developed
which have had a significant effect on any ofthe
aspects of the condition. In DAT, loss of
cholinergic neurones in the nucleus basalis and
loss of choline acetyl transferase in the
hippocampus and neocortex are the main
pathological and biochemical changes.2'3'4
Research into drugs for DAT has mainly been
directed at combating this cholinergic deficit by
reducing its breakdown through inhibiting
acetylcholinesterase. By the end of 1994 several
doubleblindclinicaltrials suggestedthattacrine,
a centrally active non-competitive reversible
acetylcholinesterase inhibitor, when prescribed
forDATmayimprovecognitiveimpairment.5 6 7 8
In 1996 evidence was published showing
improvement in cognition with donepezil
hydrochloride, a piperidine based cholinesterase
inhibitor.9' 10 In April 1997, both tacrine and
donepezilwerelicensedforuseinDAT. InMarch
1998, regional guidelines fortheuseofDrugs for
Dementia (DFD) were published by the Clinical
Resource Efficiency Support Team (CREST) on
behalf of the Department of Health and Social
Services (DHSS), Northern Ireland."1
The Antrim/Ballymena Psychiatry of Old Age
(POA) team uses a multidisciplinary consultant
ledapproachinwhichsocialworkers, community
psychiatric nurses and doctors have a role in the
assessment and management of patients. The
team, in anticipation ofthe CREST guidelines of
which they had prior knowledge through one of
theauthors (SAC) extendedits serviceinJanuary
1998 to provide a "Memory Clinic" to which
General Practitioners (GP) could refer patients
over 65 for assessment of early cognitive
impairment. Although suitability for DFD was a
prime consideration, it was intended that any
patient could be assessed whatever the cause of
theirimpairment.Assessmentcouldbeundertaken
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by any team member and protocols were
established for data collection, cognitive
assessment, prescribing and review which were
necessary to ensure adherence to the CREST
guidelines. All patients were seen by the
consultant at the first appointment to verify the
accuracy of data collected and establish the
diagnosis. It was required that for all referrals to
the memory clinic a physical examination and
necessary investigations (e.g. ECG, FBP, U&E
etc.) would be performed by the referring GP.
After the first year ofDFD use it was decided to
perform acriterionbasedauditoftheprescribing
practice of the Antrim/Ballymena POA team.
The audit objectives were to see if all patients
with DAT had been assessed for DFD, if drugs
were prescribed in accordance with CREST
guidelines and to identify any failures, why they
occurred and how they could be overcome. The
opportunity was taken to establish a database for
future audit and research on this patient
population.
METHODS
All patients seen by the Antrim/Ballymena POA
team in the period January 1 1998 to December
31 1998 wereidentifiedusingthehospitalpatient
administration system and the patient record
retrieved for audit. The inclusion criteria for
audit were that DFD were recommended or
prescribed during the audit period or that the
patient had a diagnosis of DAT or any variant
either in words orusing the ICD.IO codes FOO.0,
FOO. 1, FOO.2 and FOO.9 (pre-senile, late onset,
mixed and unspecified Alzheimer's disease
respectively).
There were no exclusion criteria.
Patient'snotesthatsatisfiedtheinclusioncriteria
wereaudited. Theauditcriteriawerebasedonthe
regional guidelines issued by CREST in March
1998. These, in essence, recommended that a
diagnosis using ICD. 10 criteria for DAT should
be made by a specialist (in old age psychiatry,
elderly care medicine orneurology), andthatthe
disease should be mild to moderate as measured
by a Mini Mental State Examination (MMSE)
score of 10 to 26.12 There should also be a shared
carearrangementinwhichtheGPwouldprescribe
as advised by the specialist and monitor side
effects, and the specialist would keep the patient
underreviewtoassessongoingneedfortreatment.
However, despite attempts to initiate formal
sharedcare agreements locally no agreementhas
beenreached. Atpresenttheauthors ofthispaper
arenotawareofany sharedcareagreementbeing
implemented anywhere in Northern Ireland so it
was decidedto acknowledge thatall cases would
be an audit failure as regards this criterion.
Demographic details, diagnosis, assessment,
follow up arrangements and whetherornot DFD
were recommended or prescribed were recorded
from the notes. Reasons for not starting or for
discontinuation of DFD were also recorded.
An audit success was that any patient diagnosed
with DAT was assessed for suitability for DFD
and any patient with mild to moderate DAT
(MMSE 10 to 26) was recommended for DFD
with follow up by the specialist according to the
CREST guidelines.
Audit failures were those patients who received
DFD without a diagnosis ofDAT, who were not
assessedinaccordancewiththeCRESTguidelines
orifthe CRESTguidelines were satisfiedbutthe
patient was not considered for DFD.
RESULTS
There were 509patients seen during theyearand
it was possible to obtain the notes of 505. The
inclusion criteria for audit were satisfied in 202
cases. The results ofthe audit are summarised in
the Table.
199 of the audited patient notes contained a
diagnosis of DAT, the remaining three cases
having a diagnosis ofmulti-infarct dementia (2)
and organic amnesia (1). All three patients had
been prescribed DFD.
In the 199 DAT cases, 100 patients were
recommended forDFD. Ofthese 98 satisfied the
audit criteria and two did not, having a MMSE
<10. These two had been started on DFD for
managementofseverebehaviourdisturbancethat
had failed to respond to all conventional
treatments. InallbutfourcasesDFDwereinitiated
by the POA team, the others being started by a
GP,aneurologist,ageriatricianandacardiologist.
In 14patientsDFD werediscontinuedbecauseof
continued cognitive decline (1), deteriorating
mentalstatei.e.irritability, aggression,delusions
andagitation(7),bradycardia(1),gastrointestinal
(UT) side effects i.e. nausea or diarrhoea (4) and
onepatientbecauseofacerebrovascularaccident.
Of the 99 DAT patients not on DFD 50 had a
MMSE < 10, 19 had no MMSE recorded and 30
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TABLE
Summary ofaudit results
Audit failures 7 CREST criteria met but DFD not offered
18 5 no MMSE recorded
3 diagnosis other than DAT but offered DFD
2 MMSE less than 10 but offered DFD
1 wrong diagnosis
Audit successes 98 CREST criteria met; DFD offered and used
184 50 CREST criteria failed and refused DFD
22 CREST criteria met, DFD offered but not used
14 MMSE impossible to record (documented)
had a MMSE score of 10-26. In the 19 cases
where no MMSE were recorded 11 were too
mentally impaired to test, one patient was too
physically ill and two patients refused testing:
they were considered valid exceptions. In five
cases noreason was given foraMMSEnotbeing
recorded.
Ofthe30DATpatients whohadanMMSEof10-
26, five patients had deteriorated cognitively
after initial assessment which had taken place
several months before the memory clinic started
and when reassessed during the audit period had
droppedbelowthelowerlimitofl0ontheMMSE.
Three hadbecomephysically ill andtwo patients
haddied. AlthoughDFDhadbeenrecommended
by the POA team three patients refused or were
non-compliant with treatment. Three further
patients did not receive DFD despite specialist
recommendation because either the GP refused
to prescribe or the family refused to dispense. In
another four cases investigation results were
pendingbeforeDFDrecommendation. DFDwere
not recommended in two patients due to
cardiovascularconductiondefects. These22were
considered valid exceptions. In seven cases no
reason was given for non-prescription of DFD
and one patient was wrongly diagnosed.
Nearly all the patients had been prescribed
donepezil as rivastigmine, another acetyl-
cholinesterase inhibitor, was only licensed for
use in May 1998, halfway through the audit
period.
Follow-up of the 100 patients commenced on
DFD occurred in 99 cases; theremainingpatient
moved away fromthe areaandhadbeenreferred
to another POA consultant.
In summary, there were 148 audit successes, 18
audit failures and 36 valid exceptions.
DISCUSSION
AlthoughCRESTguidelines suggestthatvarious
specialists may recommend treatment with DFD
the burden is falling particularly on consultants
in POA both in Northern Ireland and Great
Britain."3 In this study DFD were initiated by
doctors other than old age psychiatrists in only
four of the 100 cases. If a consultant in another
specialty recommends and a GP initiates
treatment, patients usually will be referred to
POA teams for follow up, assessment of
psychiatric orbehaviouralproblemsorforaccess
todomiciliary services. SoalthoughDFDmaybe
initiated outside POA teams at some point most
patients will become known to the local team. It
isprobabletherefore thatmostpeopleresiding in
AntrimandBallymenawhoreceivedDFDduring
1998wereseenbythisPOAservice.Theoutcome
of this prescribing audit is probably a fair
reflection of what is actually happening to the
total population receiving DFD and lessons
learnedcanbeappliedtoanyspecialistprescribing
DFD.
MostpatientsdiagnosedwithDATwereassessed
forDFD,andifprescribed,theCRESTguidelines
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were generally adhered to and follow-up was
universal. However, there were 18 auditfailures,
arate of9%. In three ofthese patients there was
afailure in prescribing i.e. DFD were prescribed
for a diagnosis other than DAT. A specialist not
recommended by CREST prescribed for one
patient with multi-infarct dementia and a
neurologist and a psychiatrist prescribed for
organic amnesia and multi-infarct dementia
respectively.
In 13 patients there was a failure in the POA
team'sassessment. NoMMSEhadbeenrecorded
infivecases;insevencases,althoughthepatients
met the CREST guidelines, DFD were not
considered and no reason given. One patient had
beenwronglydiagnosed. Thepatientsinthese 13
cases hadnotbeen assessedinthe memory clinic
but rather on domiciliary visits or in other
psychiatric clinics. It is possible that patients
werereferredforotherreasons e.g. depression or
behaviour disturbance and priority given to this
and the possibility of treatment of dementia
overlooked.
In the two cases of DFD use in DAT with a
MMSE less than 10 the indication was for
treatment ofsevere behaviourdisturbance which
hadnotrespondedtoconventionaltreatmentsi.e.
neuroleptics, antidepressives andanticonvulsants.
There is evidence that DFD can improve the
behaviourdisturbances associatedwithDAT 14,15
and in these cases families were involved in the
decision to use DFD and were aware of the
licence restrictions. There was a dramatic
improvement in one patient who was able to
return to her previous home having been
considered for an on-going care hospital bed
prior to prescription ofDFD.
A small number ofpatients (3) who agreedto the
use ofDFD were refused the drugs by the family
orthepatient's GP. Thesepatients hadexpressed
clearviews abouttreatment andthe teamfeltthat
the patients' views were valid and competent.
Subsequent family discussions and letters to the
GPsinvolveddidnotchangethesituation. Thisis
aworryingaspectofservicedeliveryandonethat
is impossible for the specialist to deal with as
family, on whom the patient depends, refuse to
fillprescriptionsoradministerthedrugs.Although
not a concern of this audit it is an ethical and
practical problem which specialists need to be
aware of and which requires further debate.
C) The Ulster Medical Society, 2000.
The failure of any grouping to produce a shared
careagreementneedstobeconsidered. Although
noagreementsexist,inrealityGPsandspecialists
are working together to provide a service. If no
difficulties are being experienced perhaps there
is no need to provide such agreements and the
CRESTguidelines shouldthereforebereviewed.
CREST should also consider including in the
guidelines indications for DFD use in severe
behaviour disturbance when conventional
treatment measures have failed.
As most audit failures occurred during the
assessment process protocols should ensure that
anyone with a diagnosis of dementia has a
recorded MMSE, that the type of dementia is
specified and that a statement is recorded for
those with DAT as to whether or not they are
suitable for DFD.
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